Early trial tests Two-Drug attack on tough cancers
NCT ID NCT03085225
Summary
This early-stage study tested whether combining two drugs—trabectedin and durvalumab—is safe and shows promise for treating advanced soft-tissue sarcoma and ovarian cancer. The trial involved 40 patients whose cancers had progressed despite previous treatments. Researchers aimed to find the safest dose and see if the combination could shrink tumors or slow their growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Bergonié
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.